Insider Selling: Eli Lilly and Company (NYSE:LLY) Major Shareholder Sells 75,510 Shares of Stock

Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 75,510 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $860.78, for a total value of $64,997,497.80. Following the completion of the transaction, the insider now directly owns 97,793,810 shares in the company, valued at $84,178,955,771.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

• On Friday, June 7th, Lilly Endowment Inc sold 139,490 shares of Eli Lilly and Company stock. The shares were sold at an average price of $852.29, for a total value of $118,885,932.10.
• On Wednesday, June 5th, Lilly Endowment Inc sold 20,383 shares of Eli Lilly and Company stock. The shares were sold at an average price of $836.32, for a total value of $17,046,710.56.
• On Monday, June 3rd, Lilly Endowment Inc sold 192,794 shares of Eli Lilly and Company stock. The shares were sold at an average price of $829.77, for a total value of $159,974,677.38.
• On Friday, May 31st, Lilly Endowment Inc sold 22,206 shares of Eli Lilly and Company stock. The shares were sold at an average price of $822.11, for a total value of $18,255,774.66.
• On Tuesday, May 28th, Lilly Endowment Inc sold 2,052 shares of Eli Lilly and Company stock. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00.
• On Friday, May 24th, Lilly Endowment Inc sold 92,563 shares of Eli Lilly and Company stock. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23.

Eli Lilly and Company Stock Up 0.1 %

Eli Lilly and Company stock traded up $0.74 during mid-day trading on Tuesday, reaching $865.74. The company’s stock had a trading volume of 3,228,775 shares, compared to its average volume of 2,959,054. The company has a market capitalization of $822.81 billion, a price-to-earnings ratio of 126.74, a price-to-earnings-growth ratio of 1.85 and a beta of 0.36. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $882.14. The business’s 50 day simple moving average is $777.92 and its 200 day simple moving average is $711.44. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.62 earnings per share. As a group, research analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 10th. Investors of record on Thursday, May 16th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date of this dividend was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LLY. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Citigroup boosted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. The Goldman Sachs Group lifted their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Tuesday. Finally, Argus lifted their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $787.53.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in LLY. Campbell & CO Investment Adviser LLC acquired a new stake in Eli Lilly and Company in the third quarter valued at $234,000. Alliance Wealth Advisors LLC UT acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $599,000. Valley Wealth Managers Inc. lifted its stake in shares of Eli Lilly and Company by 1.3% during the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after buying an additional 17 shares during the last quarter. Cyrus J. Lawrence LLC lifted its stake in shares of Eli Lilly and Company by 1.1% during the 3rd quarter. Cyrus J. Lawrence LLC now owns 21,653 shares of the company’s stock worth $11,630,000 after buying an additional 238 shares during the last quarter. Finally, Houlihan Financial Resource Group Ltd. acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $271,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.